Baxter (BAX) Q4 2024 Earnings Call Transcript

Baxter reported Q4 continuing-operations revenue of $2.75 billion, up 1% reported and 2% constant currency, with adjusted EPS of $0.58 versus guidance of $0.50-$0.53. Full-year sales rose 3% to $10.6 billion and adjusted EPS increased 11% to $1.89, while the company signaled 2025 sales growth of 5%-6% and EPS of $2.45-$2.55. Results were tempered by a $110 million Hurricane Helene hit in Q4, but recovery at North Cove, strong Novum IQ launch momentum, and nearly $3 billion of debt paydown support the outlook.

Analysis

BAX is transitioning from a “fix-and-separate” story into a cleaner operating-leverage story, and that changes the stock’s setup. The key second-order effect is that the post-Vantive capital structure plus TSA income gives management a temporary margin cushion while stranded-cost removal creates an earnings glidepath that can outpace revenue growth for several quarters. That makes 2025 less about top-line perfection and more about whether execution discipline can turn a mid-single-digit sales profile into high-single-digit EPS growth.

The most underappreciated positive is the competitive durability of the North Cove recovery. Customers that would normally multi-source during a disruption appear to have largely stayed put, which reduces the risk that the hurricane permanently resets share in saline/IV solutions. If that holds through the next two quarters, the market may have overestimated the lasting share loss and underestimated the pricing power embedded in Baxter’s installed base and GPO footprint.

The main bearish risk is that the current guidance embeds several “temporary supports” that fade: TSA income, favorable mix from launch ramps, and working-capital normalization after Q1. If product launches slip or FLC/CCS recovery proves slower, the margin bridge becomes much less impressive once the hurricane comps roll off. The CEO search is a real wildcard too: a strategic reset could improve the long-term multiple, but near-term it also raises the probability of pause on buybacks/capital deployment until the new leader re-underwrites the portfolio.

Consensus is probably still too anchored to Baxter as a low-growth, event-driven healthcare name. The more interesting read is that the company’s operational reset is creating a path to a higher-quality earnings base, and the market may be slow to re-rate that until it sees one more quarter of uninterrupted recovery plus proof that free cash flow snaps back after the Q1 working-capital dip.

Key Decisions for Investors

• Go long BAX on a 3-6 month horizon; best entry is any post-earnings fade below the guidance-implied multiple, with a target move on evidence of Q1 recovery and leverage progress. Risk/reward: asymmetric if North Cove-driven share retention persists and margin bridge holds.
• Sell downside via BAX put spreads 1-2 quarters out, sized around the Q1 cash flow trough. Thesis: the first-quarter working-capital drag is visible and likely already in the numbers, while downside is cushioned by continued TSA income and debt paydown.
• Pair trade: long BAX / short HCA or other defensive healthcare compounders if you want idiosyncratic recovery exposure rather than macro healthcare beta. This isolates execution upside from BAX’s margin repair without paying for broad-sector defensiveness.
• For event-driven accounts, consider a small long position into the CEO-search catalyst and add only after clarity on capital allocation priorities. The risk is a strategic review that delays buybacks; the reward is a re-rating if the new CEO is viewed as an operator who accelerates innovation and de-stranding.
• Avoid chasing HST-related strength via standalone trades until FLC stabilizes for another quarter; the turnaround is credible but still has the highest execution variance, so the cleaner expression is the parent rather than a pure supply-chain/capital-equipment read-through.